Compare GSUN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | SCNX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | China | United States |
| Employees | N/A | 9 |
| Industry | Other Consumer Services | Other Pharmaceuticals |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 4.4M |
| IPO Year | 2020 | 2019 |
| Metric | GSUN | SCNX |
|---|---|---|
| Price | $0.12 | $2.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 257.2K | 26.4K |
| Earning Date | 08-19-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $620.33 |
| Revenue Next Year | N/A | $397.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.13 | $2.24 |
| 52 Week High | $1.62 | $106.25 |
| Indicator | GSUN | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 21.54 | 44.57 |
| Support Level | N/A | N/A |
| Resistance Level | $0.19 | $3.68 |
| Average True Range (ATR) | 0.01 | 0.30 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 14.40 | 8.84 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.